Lupus Trials News

The best and brightest are working toward finding better treatments and ultimately a cure for lupus. Read about how the most important influencers in the lupus community are effecting lupus research, along with other issues that matter most to you.

A “Call to Arms” for the Lupus Community

August 18, 2021 Many lupus patients are at risk for COVID-19 infection because of treatment with corticosteroids and other immunosuppressive medications and will be eligible for booster vaccination. However, there are large gaps in our understanding of who will benefit from the booster vaccines, what strategies will improve response to the vaccine and the best […]

Two Studies Show COVID-19 Vaccines are Well-Tolerated Among Lupus Patients

August 12, 2021 In two recent studies, researchers found that the four COVID-19 vaccines are well-tolerated in lupus patients. Given that the Moderna and Pfizer vaccines are the first mRNA vaccines currently authorized for the emergency use in people, lupus researchers have since worked to answer questions specifically about potential side effects and whether these […]

Important Message from CEO Kenneth Farber: U.S. FDA Approves New Lupus Treatment

August 2, 2021 Dear Friend of the Lupus Research Alliance, As we reported this morning, the lupus community has much to celebrate with the U.S. Food and Drug Administration (FDA) approval of anifrolumab-fnia (brand name, Saphnelo™). As a first-in-class and only new treatment for systemic lupus erythematosus in a decade, this approval marks a major […]

Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca’s anifrolumab-fnia (Saphnelo™) for Systemic Lupus Erythematosus (SLE)

  First in New Class of Drugs in More than a Decade for SLE Targeting Type 1 Interferons NEW YORK, NY. August 2, 2021. The Lupus Research Alliance (LRA) is particularly excited about the U.S. Food and Drug Administration (FDA) approval of anifrolumab-fnia (Saphnelo™), a first-in-class type I interferon receptor antagonist indicated for adults with […]

Two New Drugs Receive FDA Approval

May 1, 2021 “This is a historic moment in lupus with two new drug approvals for lupus nephritis in just over a month,” enthused Kenneth M. Farber, LRA President and CEO. The LRA is excited to share that the U.S. Food and Drug Administration (FDA) has approved the use of voclosporin (Lupkynis™) as the first […]

LRA Writes President Supporting Dr. Janet Woodcock for FDA Commissioner

March 31, 2021 As part of the LRA’s mission to accelerate development and availability of much-needed new diagnostics and treatments for lupus, the organization’s President and CEO, Mr. Kenneth M. Farber, submitted a letter to President Joseph Biden to express LRA’s strong support for Dr. Janet Woodcock to be nominated for Commissioner of the U.S. […]

LRA Congratulates Equillium on Positive Results of Study of Potential New Lupus Treatment

March 30, 2021 Equillium, Inc. announced positive topline data from the phase 1b EQUALISE study in patients with systemic lupus erythematosus (SLE).  This study suggests that itolizumab, a monoclonal antibody selectively targeting the CD6-ALCAM pathway, was safe and well tolerated among people with SLE. [Source: Equillium, Inc. Press Release 3.30.21] The EQUALISE study is evaluating […]

Join LRA’s Interactive, Virtual Lupus Clinical Trials Fair on April 8th!

Join LRA’s Interactive, Virtual Lupus Clinical Trials Fair on April 8th! ·    Learn more about an upcoming study LRA is doing on COVID-19 vaccines in people with lupus ·    Network and talk to people who’ve been in a lupus trial ·    Speak with the researchers conducting lupus trials near you ·    Compete for prizes…and MUCH MORE Click here to […]

Lupus Research Alliance Hails Approval of Aurinia’s Lupkynis(TM) (voclosoporin)

First Oral Treatment for Lupus Nephritis; Second Lupus Treatment to Receive FDA Approval in Past Month NEW YORK, NY. January 22, 2021. The Lupus Research Alliance (LRA) is excited to share that the U.S. Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals’ LupkynisTM (voclosporin) as the first oral treatment developed specifically for […]

LuCIN Investigators Show that Stimulating the Vagus Nerve in Lupus Patients Decreases Pain and Fatigue

November 23, 2020 Up to 95% of lupus patients report pain and fatigue caused by the disease. To explore ways to fix this, a research team led by Dr. Cynthia Aranow at The Feinstein Institutes for Medical Research studied whether lessening inflammation in patients with lupus would also lessen pain and fatigue. In this study, […]

Promising New Lupus Treatments Highlighted ACR Annual Meeting

Results of clinical trials testing potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2020. These studies include phase I trials, which test for side effects and a safe dosage; larger phase II trials, which test for effectiveness and further gauge safety; and large phase III trials, which confirm […]

LRA Highlights Full Continuum of Lupus Research at ACR Convergence 2020

30+ presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways Results from three clinical studies conducted in part by LRA-affiliate Lupus Therapeutics (LT) through its trials network 10 lupus presentations by the Accelerating Medicines Partnership Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) program (AMP RA/SLE) NEW YORK, NY, […]

Results of Two Voclosporin Trials Presented at Key Medical Meeting

October 22, 2020 Aurinia Pharmaceuticals announced that data taken from a combined analysis of two trials, AURA-LV and AURORA underscored the potential for voclosporin to offer a tool to treat lupus nephritis. Results from 534 patients from both trials was presented at the American Society of Nephrology Kidney Week 2020 meeting by Dr. Brad Rovin, […]

LRA-Supported Researcher Finds Similarity between COVID-19 and Lupus Flares

October 21, 2020 In a recent study published in Nature Immunology, LRA Lupus Insight Prize recipient Dr. Ignacio Sanz and colleagues found that the immune response in patients hospitalized with  severe COVID-19 was different from that in patients with mild disease, and that the immune response in severely ill COVID-19 patients was more like a lupus flare. They saw that among severely ill COVID-19 patients, some immune cells called B cells reproduced unchecked, and […]

Lupus Clinical Trials Redefined: You Make the Difference

Lupus Clinical Trials Redefined: You Make the Difference Lupus Clinical Trials Virtual Fair October 17, 2020 10:00 am to 1:00 pm ET Register Here Lupus clinical trials are still underway despite COVID-19. Making the process safer and easier for patients has never been more important. What is a clinical trial exactly? Why should I get involved […]

LRA Applauds GSK on Positive Phase 3 Study of Benlysta® in Lupus Nephritis

September 16, 2020 NEW YORK, NY. The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week’s New England Journal of Medicine, demonstrating that GSK’s drug Benlysta® (belimumab) significantly improved kidney function in adults with lupus nephritis, the most common severe complication of lupus causing inflammation and serious damage to the kidney. The […]

Lupus Therapeutics Collaborating with PPD to Accelerate Lupus Clinical Research

September 3, 2020 PPD, Inc. issued a press release  today announcing its collaboration with the Lupus Research Alliance affiliate Lupus Therapeutics to optimize lupus clinical research among its pharmaceutical and biotech clients. As a contract research organization, PPD helps its clients design and implement clinical trials. PPD expects to gain from Lupus Therapeutics’ deep clinical […]

23andMe Study Confirms Lupus Can Run in Families and Other New Insights

August 25, 2020 A study started four years ago and conducted by 23andMe provided many insights about lupus as a complex disease that is extremely difficult to diagnose and treat. While the survey of nearly 6,000 participants did not find new genetic factors causing lupus as hoped, the study confirmed that lupus can run in […]

Study Suggests Older Lupus Patients May Stop Hydroxychloroquine Without Raising Risk for Flares

August 18, 2020 A newly published study conducted by many of the research investigators who receive grant support from the Lupus Research Alliance found that older people with lupus may be able to discontinue their use of hydroxychloroquine. Investigators conducted this study because prolonged use of the drug can cause side effects like blurred vision […]

2018 LRA Lupus Insight Prize Recipient Receives $15 M Grant from NIH to Study Lupus Effects on the Brain

July 27, 2020 The Lupus Research Alliance congratulates 2018 Lupus Insight Prize recipient Betty Diamond, MD and the Feinstein Institutes for Medical Research on being awarded $15 million from the National Institute of Allergy and Infectious Disease to study brain dysfunction linked to lupus. Dr. Diamond will use the five-year grant to study a receptor […]

New Data Showed Safety and Effectiveness of Benlysta for Kids

July 27, 2020 A new international study published in Annals of the Rheumatic Diseases showed that belimumab (Benlysta) was safe and effective when given intravenously to children. In this Phase 2, randomized, placebo-controlled, blinded study, 93 patients 5-17 years of age received standard therapy plus either placebo or belimumab. As measured by commonly used tools, […]

LRA Statement: Potential Lupus Nephritis Drug Voclosporin Granted Priority Review by the U.S. FDA

NEW YORK, NY. July 22. The Lupus Research Alliance congratulates Aurinia Pharmaceuticals Inc. on acceptance of its NDA filing and priority review designation by the U.S. Food and Drug Administration for its investigational drug voclosporin for lupus nephritis. A serious inflammation of the kidneys, lupus nephritis is one of the most common complications of systemic […]

Lupus Research Alliance Response to Janssen’s Ustekinumab Lupus Trial Discontinuation

June 26, 2020 The Lupus Research Alliance is disappointed at news from Janssen Pharmaceutical Companies of Johnson & Johnson that it has decided to discontinue the Phase 3 LOTUS study of ustekinumab (Stelara®) in Systemic Lupus Erythematosus (SLE). A Phase 3 trial presents data the U.S. Food and Drug Administration uses to decide whether or […]

New Study Presents Strategies That Helped African-Americans Take Part In Lupus Trials

June 22, 2020 African-Americans are more likely to develop lupus than Caucasians, but less likely to take part in clinical trials of the disease. However, a new study showed that several simple steps, such as providing transportation and flexible scheduling, may allow more African-Americans to participate in trials. The study was conducted by top lupus […]

Promising News from Major Medical Meeting, EULAR

Updated June 5, 2020 One of the largest meetings for rheumatologists went virtual this year to enable scientists from around the world to share their latest findings amid the COVID-19 pandemic. EULAR, the e-Congress of the European League Against Rheumatism, runs June 3 -6, and LRA is pleased to share promising results from clinical trials […]

End of content

No more pages to load